公开(公告)号：US20240327481A1

公开(公告)日：2024-10-03

申请号：US18746427

申请日：2024-06-18

Applicant: AMGEN INC.

Inventor： YuMei XIONG ,  Kenneth William WALKER ,  Murielle Marie VENIANT ELLISON

IPC: C07K14/495 ,  A61K38/00

CPC classification number: C07K14/495 ,  A61K38/00 ,  C07K2319/30

Abstract: GDF15 molecules are provided herein. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, in which a GDF15 region is fused to an Fc region. In some embodiments, the GDF15 region is fused to the Fc region via a linker. Also, provided herein arr methods for making and using GDF15 molecules.

公开(公告)号：US20210017261A1

公开(公告)日：2021-01-21

申请号：US16919032

申请日：2020-07-01

Applicant: AMGEN INC.

Inventor： Neeraj Jagdish AGRAWAL ,  Irwin CHEN ,  Su CHONG ,  Bryna FUCHSLOCHER ,  Kevin GRAHAM ,  Agnes Eva HAMBURGER ,  Mark Leo MICHAELS ,  Christopher MOHR ,  Derek E. PIPER ,  Kenneth William WALKER ,  Zhulun WANG ,  Cen XU

IPC: C07K16/18 ,  C07K16/28 ,  A61P25/06 ,  A61K38/22

Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

公开(公告)号：US20240150448A1

公开(公告)日：2024-05-09

申请号：US18545688

申请日：2023-12-19

Applicant: AMGEN INC.

Inventor： Neeraj Jagdish AGRAWAL ,  Irwin CHEN ,  Su CHONG ,  Bryna FUCHSLOCHER ,  Kevin GRAHAM ,  Agnes Eva HAMBURGER ,  Mark Leo MICHAELS ,  Christopher MOHR ,  Derek E. PIPER ,  Kenneth William WALKER ,  Zhulun WANG ,  Cen XU

IPC: C07K16/18 ,  A61K38/22 ,  A61P25/06 ,  C07K16/28

CPC classification number: C07K16/18 ,  A61K38/2278 ,  A61P25/06 ,  C07K16/2869 ,  A61K2039/545 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/92

Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

公开(公告)号：US20220363770A1

公开(公告)日：2022-11-17

申请号：US17621189

申请日：2020-06-26

Applicant: AMGEN INC.

Inventor： Irwin CHEN ,  Su CHONG ,  Fernando GARCES ,  Mark Leo MICHAELS ,  Christopher MOHR ,  Kenneth William WALKER ,  Zhulun WANG ,  Neeraj Jagdish AGRAWAL ,  Bryna FUCHSLOCHER ,  Kevin GRAHAM ,  Agnes Eva HAMBURGER ,  Derek E. PIPER ,  Cen XU

IPC: C07K16/28 ,  C07K16/46

Abstract: The present invention relates to antagonist antibodies of the human calcitonin gene-related peptide (CGRP) receptor as well as bispecific antigen binding proteins derived from the anti-CGRP antibodies that bind to and inhibit both the human CGRP receptor and another target, such as the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) receptor. Pharmaceutical compositions comprising the anti-CGRP receptor antibodies and bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the anti-CGRP receptor antibodies and bispecific antigen binding proteins to ameliorate, treat, or prevent conditions associated with the CGRP and PAC1 receptors, such as chronic pain, migraine, and cluster headache, are also described.

公开(公告)号：US20220195022A1

公开(公告)日：2022-06-23

申请号：US17558032

申请日：2021-12-21

Applicant: AMGEN INC.

Inventor： Neeraj Jagdish AGRAWAL ,  Irwin CHEN ,  Su CHONG ,  Bryna FUCHSLOCHER ,  Kevin GRAHAM ,  Agnes Eva HAMBURGER ,  Mark Leo MICHAELS ,  Christopher MOHR ,  Derek E. PIPER ,  Kenneth William WALKER ,  Zhulun WANG ,  Cen XU

IPC: C07K16/18 ,  C07K16/28 ,  A61P25/06 ,  A61K38/22

Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

公开(公告)号：US20230143988A1

公开(公告)日：2023-05-11

申请号：US16620029

申请日：2019-04-08

Applicant: Amgen Inc.

Inventor： YuMei XIONG ,  Kenneth William WALKER ,  Murielle Marie VENIANT ELLISON

IPC: C07K14/495

CPC classification number: C07K14/495 ,  C07K2319/30

Abstract: GDF15 molecules are provided herein. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, in which a GDF15 region is fused to an Fc region. In some embodiments, the GDF15 region is fused to the Fc region via a linker. Also, provided herein are methods for making and using GDF15 molecules.

公开(公告)号：US20210147500A1

公开(公告)日：2021-05-20

申请号：US17148761

申请日：2021-01-14

Applicant: Amgen Inc.

Inventor： YuMei XIONG ,  Kenneth William WALKER ,  Murielle Marie VENIANT ELLISON

IPC: C07K14/495

Abstract: GDF15 molecules are provided herein. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, in which a GDF15 region is fused to an Fc region. In some embodiments, the GDF15 region is fused to the Fc region via a linker. Also, provided herein are methods for making and using GDF15 molecules.

公开(公告)号：US20210079051A1

公开(公告)日：2021-03-18

申请号：US17094968

申请日：2020-11-11

Applicant: AMGEN INC.

Inventor： Yumei XIONG ,  Yi ZHANG ,  Jackie Z. ZHENG ,  Agnes Eva HAMBURGER ,  Murielle M. VENIANT-ELLISON ,  Grant SHIMAMOTO ,  Xiaoshan MIN ,  Zhulun WANG ,  Jie TANG ,  Gunasekaran KANNAN ,  Marissa MOCK ,  Kenneth William WALKER

IPC: C07K14/475

Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

公开(公告)号：US20240368236A1

公开(公告)日：2024-11-07

申请号：US18639202

申请日：2024-04-18

Applicant: Amgen Inc.

Inventor： Yumei XIONG ,  Yi ZHANG ,  Jackie Z. SHENG ,  Agnes Eva HAMBURGER ,  Murielle M. VENIANT-ELLISON ,  Grant SHIMAMOTO ,  Xiaoshan MIN ,  Zhulun WANG ,  Jie TANG ,  Gunasekaran KANNAN ,  Marissa MOCK ,  Kenneth William WALKER

IPC: C07K14/475

Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.

公开(公告)号：US20220324924A1

公开(公告)日：2022-10-13

申请号：US17624824

申请日：2020-07-06

Applicant: AMGEN INC.

Inventor： Kenneth William WALKER

IPC: C07K14/47 ,  C12N5/071 ,  C12N15/85 ,  C12N15/62 ,  C12P21/02

Abstract: The present invention relates to multispecific transthyretin (TTR) complexes useful as multispecific binding proteins. The multispecific TTR complexes described herein are particularly useful in binding to one, two, or more epitopes which may be present on one or more proteins. Methods for treating diseases using the TTR complexes of the present invention are described herein.